Abstract
The PLATO study suggested that higher aspirin doses may be inferior in ticagrelor treated patients with acute coronary syndromes (ACS). Reducing bleeding risk whilst maintaining antithrombotic benefits would improve outcomes. We characterised a novel regimen of ultra-low-dose aspirin given twice
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
